Dr. Vance Andrew Broach, MD

Dr. Broach practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Broach's NPI, 1063649085, was assigned on June 17, 2009. Dr. Broach graduated from Pritzker School of Medicine in 2009. Dr. Broach holds New York license 269005.

Dr. Broach's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Broach's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Broach is also affiliated with Stony Brook University Hospital. The medical group on file is Memorial Sloan Kettering Cancer Center (MSK), Department of Surgery. Dmand AI also links Dr. Broach to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Broach practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Broach's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Broach is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Broach's licenses on file in 3 states: New York, New Jersey and Illinois.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Broach treats.

CMS data shows 374 Medicare services from Dr. Broach across 7 procedure codes in 2024, for 241 Medicare patients. Medicare paid $34,204 for them. Every service was in an office.

CMS counts 241 Medicare patients who saw Dr. Broach in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Broach's median patient age at 69, with 97% women.

In 2024, Dr. Broach wrote 11 Medicare Part D claims. 100% of them were for generic drugs. They cover 1 drug, with $1,590 in total drug cost. In 2019, CMS named 29 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Broach for performance year 2024, reported as part of a group. Dr. Broach accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Broach as offering telehealth. CMS counts 32 procedures of removal of the uterus by Dr. Broach, more than 97% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 67 papers to Dr. Broach, published from 2007 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Ovarian Neoplasms, Cytoreduction Surgical Procedures and Genital Neoplasms, Female. Dr. Broach has published most often in Gynecol Oncol. Dr. Broach's most frequent co-authors are Mario Mendes Leitao, MD, Yukio Sonoda, MD and Nadeem R. Abu-Rustum, MD.

Dmand AI links Dr. Broach to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Vulvar Neoplasms and Vulvar Diseases. Memorial Sloan Kettering Cancer Center sponsors the most, 2.

CMS Open Payments shows 72 general payments to Dr. Broach from 10 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 50% of the total. Intuitive Surgical, Inc. paid the most, $4,663.

Dr. Broach graduated from Pritzker School of Medicine in 2009.

Dr. Broach is in network with 10 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.